Gastrointestinal Chemotherapy Tweak Can Reduce Side Effects | Inside Precision Medicine
A multicenter study of 11,000+ patients found that omitting the bolus component of 5-fluorouracil (5-FU) in multidrug chemotherapy for advanced gastrointestinal cancers reduces side effects without affecting survival.
Reference News
Omitting 5-fluorouracil (5-FU) from first-line multidrug regimens in advanced gastrointestinal cancers reduced toxicity without compromising efficacy, according to a study in the Journal of the National Comprehensive Cancer Network. No significant difference in overall survival was found when 5-FU bolus was omitted, regardless of regimen or cancer type. The study suggests that the bolus component of 5-FU may not be necessary.
A multicenter study of 11,000+ patients found that omitting the bolus component of 5-fluorouracil (5-FU) in multidrug chemotherapy for advanced gastrointestinal cancers reduces side effects without affecting survival.